TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02741648

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
Study: NCT03943797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultivated oral mucosal epithelial cell transplantation
Description: Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
Study: NCT00931112

Intervention type: OTHER
Group type: OTHER
Intervention: individualized exercise training
Description: Lower extremities resistance exercise and bicycle training
Study: NCT04143711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.
Study: NCT01027468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intraocular bevacizumab injection
Study: NCT01749046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remegal
Description: Remegal 1500 mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remegal
Description: Remegal 1500 mg for 12 weeks
Study: NCT04171193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Pill
Description: Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
Study: NCT04241016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sinus surgery (ESS)
Description: Uncinectomy, middle meatal antrostomy by enlarging the natural maxillary ostium and partial ethmoidectomy or septoplasty according to clinical evaluation of the operator.
Study: NCT03235323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counterpulsation
Description: ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
Study: NCT02144077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-200 ALA
Description: Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl-aminolevulinate
Description: Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
Study: NCT04143711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.
Study: NCT03620149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Denosumab 120 mg, SC, on day 1 of every 12-week cycle
Study: NCT04135755

Intervention type: OTHER
Intervention: no drug intervention
Description: no drug or treatment intervention

Intervention type: OTHER
Intervention: no drug intervention
Description: no drug or treatment intervention

Intervention type: OTHER
Intervention: no drug intervention
Description: no drug or treatment intervention
Study: NCT01345214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7746
Description: 10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
Study: NCT04143711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 immunotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: A chemotherapy treatment combining paclitaxel with albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: A chemotherapy treatment combining paclitaxel with albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate
Study: NCT01369745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 2.7 mg daily
Study: NCT04143711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate
Study: NCT01065454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: up to 1 mg three times a day (increasing from 0.5 to 1 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: fixed 0.5 mg three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a day
Study: NCT03157128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-292
Description: Oral LOXO-292
Study: NCT01369745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dipyridamole
Description: dipyridamole 360 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z102
Description: Prednisolone 2.7 mg plus dipyridamole 360 mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02861963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RVOT reconstruction by femoral allogenic vein valve conduit
Description: Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic-to-pulmonary artery shunts
Description: Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side.
Study: NCT03953521

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent Theta burst stimulation
Description: Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta burst stimulation
Description: Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
Study: NCT02809950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral carbohydrate beverage
Description: oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: NPO from midnight of the day before surgery
Study: NCT04493372

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic inhibition
Description: Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic inhibition
Description: Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic activation
Description: Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic activation
Description: Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing of autonomic dysreflexia
Description: Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing of autonomic dysreflexia
Description: Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
Study: NCT02754518

Intervention type: DRUG
Group type: OTHER
Intervention: Entresto
Study: NCT00943397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Usual Care
Description: Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
Study: NCT04504578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contact lens assisted corneal cross linking
Description: 40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch \& Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
Study: NCT03317717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
Study: NCT03777280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peek framework RPD
Description: it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt chromium framework RPD
Description: standard framework device
Study: NCT00460239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular; double blind; once per week
Study: NCT04026230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Capsules including 80 mg of atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Study: NCT01084902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide
Description: Two times daily
Study: NCT00866957

Intervention type: PROCEDURE
Intervention: Blood draw
Description: A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
Study: NCT02285075

Intervention type: DRUG
Group type: OTHER
Intervention: temocillin PK/PD in haemodialysis
Description: Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T \> MIC of 8 and 16 mg/L).
Study: NCT02482883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.
Study: NCT01911754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)
Study: NCT00301457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg once daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg once daily oral dose
Study: NCT04621032

Intervention type: DIAGNOSTIC_TEST
Intervention: Polygraphy monitoring
Description: All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polygraphy monitoring
Description: All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory tests
Description: Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory tests
Description: Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
Study: NCT02951026

Intervention type: OTHER
Intervention: Not applicable (no therapy is administered as part of this study)
Description: No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study.

Intervention type: OTHER
Intervention: Not applicable (no therapy is administered as part of this study)
Description: No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study.

Intervention type: OTHER
Intervention: Not applicable (no therapy is administered as part of this study)
Description: No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study.

Intervention type: OTHER
Intervention: Not applicable (no therapy is administered as part of this study)
Description: No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study.
Study: NCT01535443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: Drug: Bromfenac Other names: PRO-155
Study: NCT02875795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automatic speech processing tool